AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04784039 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: D-Dimer analysis
Description: Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion
Study NCT04567498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
Study NCT06174402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study NCT05435014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-ACE Oil
Description: TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Study NCT06457958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Group
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Study NCT06457958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Group
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Study NCT04631692 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health literacy intervention
Description: We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant.
Study NCT06152172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYV-101
Description: The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
Study NCT06152172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
Study NCT04232254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-based Protein Foods
Description: Participants will consume animal-based protein foods.
Study NCT04232254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based Protein Foods
Description: Participants will consume animal-based protein foods.
Study NCT04232254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skewed Protein Distribution
Description: Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
Study NCT04232254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skewed Protein Distribution
Description: Participants will consume 3 meals per day consisting of 10-, 30-, 60% of dietary protein for breakfast, lunch, and dinner, respectively.
Study NCT04232254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based Protein Foods
Description: Participants will consume plant-based protein foods.
Study NCT04232254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balanced Protein Distribution
Description: Participants will consume 5 meals per day consisting of 20% of dietary protein per meal.
Study NCT06469593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated insuling delivery system
Description: Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
Study NCT04803539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
Study NCT04803539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine + camrelizumab + apatinib
Description: Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
Study NCT04880733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture for pain management
Description: A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
Study NCT04880733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care for pain management
Description: Patient will receive usual care for pain management.
Study NCT05406141 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid formula (Neocate Jr)
Description: Use Neocate Jr for 4 weeks, either as sole source of nutrition or oral nutritional supplement:~* Sole source of nutrition: as far as possible >7 days, especially newly diagnosed allergy children~* Oral nutritional supplement (Neocate Jr ≥50% of daily total energy and the rest provided by food)
Study NCT05095454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous epidural electrical spinal stimulation
Description: Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Ripple Neuromed Nomad Neurostimulation System
Study NCT05095454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical spinal stimulation
Description: Digitimer DS8R Bipolar Constant Current Stimulator
Study NCT04880733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for pain management
Description: Patient will receive usual care for pain management.
Study NCT05435014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipiodol
Description: TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
Study NCT06152172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
Study NCT06592742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (alone)
Description: The Pulmonary Rehabilitation (PR) program for the control group includes daily aerobic exercises such as treadmill walking or cycling for 20-30 minutes at moderate intensity, tailored to improve cardiovascular fitness and respiratory function. Strength training focuses on major muscle groups with resistance exercises lasting 15-20 minutes, promoting muscle strength and endurance. Airway clearance techniques are performed for 15-20 minutes daily, using methods like chest physiotherapy or positive expiratory pressure (PEP) to clear mucus from the lungs. Breathing exercises, including diaphragmatic and pursed-lip breathing, are practiced for 10-15 minutes to improve breathing efficiency. Participants also receive education on disease management and nutritional support to meet caloric needs.
Study NCT06592742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (PR + PMR)
Description: The intervention group will follow a Pulmonary Rehabilitation (PR) program combined with Progressive Muscle Relaxation (PMR). Daily aerobic exercises like treadmill walking or cycling will be performed for 20-30 minutes at moderate intensity, improving cardiovascular fitness and lung function. Strength training for major muscle groups will be included, with 15-20 minutes of resistance exercises to enhance muscle strength. Airway clearance techniques, such as chest physiotherapy or PEP, will help clear mucus from the lungs in daily 15-20 minute sessions. Breathing exercises, including diaphragmatic and pursed-lip breathing, will be practiced for 10-15 minutes to improve breathing efficiency. The PMR component involves daily 20-30 minute guided sessions to reduce stress and anxiety through muscle relaxation techniques.
Study NCT06616610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention with the Mobility Platform
Description: The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.
Study NCT06616610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention with Traditional Therapy
Description: The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
Study NCT05304871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: infusion
Study NCT05304871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: infusion
Study NCT06376916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 2 G
Description: Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Study NCT06376916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 4 G
Description: Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Study NCT06376916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Study NCT05454514 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HiDO medication adherence platform
Description: The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
Study NCT05454514 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Automated Medication Platform with Video Observation
Description: There is no drug intervention. The device elicits increases adherence of medications.
Study NCT05849090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin or clindamycin/vancomycin antibiotics..
Description: Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
Study NCT05849090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin and Tobramycin antibiotics.
Description: Vancomycin (1 gram) and tobramycin (1.2 grams).
Study NCT06331598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
Study NCT06331598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: A dose of 840 mg tiragolumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
Study NCT05513703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion
Study NCT05599126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mianserin
Description: Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
Study NCT05599126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
Study NCT05454514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time on Task
Description: Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
Study NCT05319730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion, administered every Q3W.
Study NCT05319730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg IV infusion, administered Q3W up to 35 infusions.
Study NCT06315400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin®
Description: 60 mg/day for 5 days
Study NCT06315400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day for 5 days
Study NCT05319730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg oral administration every day.
Study NCT05969236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDI-1228_mesylate Ophthalmic Solution
Description: MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)
Study NCT05969236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
Study NCT05591001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and dexmeditomidine combination
Description: Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion
Study NCT05591001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol (100 ug /kg/min) infusion
Study NCT05593042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.
Study NCT05593042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron Vaccine
Description: An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant.
Study NCT05593042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Vaccine
Description: An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant).
Study NCT06616363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A fMRI scan
Description: • Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
Study NCT04841733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Roller (FR)
Description: Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
Study NCT04841733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching (STR)
Description: Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
Study NCT04841733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold-Water Immersion (CWI)
Description: Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
Study NCT06616363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A bedside tilt test will be performed
Description: A bedside tilt test will be performed where blood pressure will be recorded supine and upright positions to confirm/exclude POTS.
Study NCT06616363 — intervention group
Intervention type: OTHER
Intervention: IV placed to collect blood samples
Description: • An IV will be place for collection of 4 blood samples, about 12 mL of blood. For each position (lying and standing) the study team will draw 2 tubes each times with 3 mL of blood, for a total of 4 lab tubes (12 mL). Physical exams to assess the 18-tender points described by the American College of Rheumatology for the diagnosis of fibromyalgia and hypermobility/Ehlers-Danlos Syndrome (EDS) exam will be performed in all subjects.
Study NCT06616363 — intervention group
Intervention type: OTHER
Intervention: Stool Sample
Description: • Participants will provide a stool biospecimen sample at each in-person visit. Stool will be collected in a hat and sample will be swabbed with the swab placed directly into PrimeStore collection tube and the remainder of the sample discarded
Study NCT06616259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mCapOX plus Cetuximab
Description: mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy.
Study NCT06616259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 plus Cetuximab
Description: mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy.
Study NCT06617000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG101
Description: Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
Study NCT06617507 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.